These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31220093)

  • 1. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
    Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
    PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
    Graillon T; Defilles C; Mohamed A; Lisbonis C; Germanetti AL; Chinot O; Figarella-Branger D; Roche PH; Adetchessi T; Fuentes S; Metellus P; Dufour H; Enjalbert A; Barlier A
    J Neurooncol; 2015 Aug; 124(1):33-43. PubMed ID: 26015296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
    Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
    J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
    J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
    Le Van T; Graillon T; Jacob J; Vauleon E; Feuvret L; Boch AL; Boetto J; Boone M; Bronnimann C; Caire F; De Barros A; Delaitre M; Di Stefano AL; Dore M; Ducray F; Dufour C; Engelhardt J; Fontaine D; Froelich S; Helleringer M; Huchet A; Joncour A; Jouanneau E; Mallereau CH; Monfilliette A; Le Fur E; Zemmoura I; Chinot O; Sanson M; Kalamarides M; Loiseau H; Peyre M
    J Neurooncol; 2021 May; 153(1):55-64. PubMed ID: 33778930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
    Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
    Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.
    Pfister C; Pfrommer H; Tatagiba MS; Roser F
    Br J Cancer; 2012 Nov; 107(10):1702-13. PubMed ID: 23047550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
    Graillon T; Tabouret E; Chinot O
    Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.
    Raheja A; Colman H; Palmer CA; Couldwell WT
    J Neurosurg; 2017 Nov; 127(5):965-970. PubMed ID: 27935362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
    Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
    J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
    Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
    J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.